Search
Entacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. … When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration
Products: ENTACAPONE MYLAN GENERICSAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … [L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384]
Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawnAcetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in t...
Mepyramine
go.drugbank.com/drugs/DB06691ApprovedVet approvedHowever, it rapidly permeates the brain and so often causes drowsiness as a side effect. … It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
Mixtures: Midol OneBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalCompared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … [L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalIt has one chiral center and is the R-stereoisomer.[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591]
Phosphoric acid
go.drugbank.com/drugs/DB09394ApprovedInvestigationalPhosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.
Mixtures: Butler Protect One Minute Apf Fluoride GelUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalIn October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients.
AT-GTX-502
go.drugbank.com/drugs/DB17001ExperimentalAT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.
Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalIn January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.